Author

Yu Chi Yang

Revolution Medicines (United States)ORCID 0000-0001-8318-1174Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:benchmark study· 1 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

Alison M. SchramiD· 1 shared Britta WeigeltiD· 1 shared Elisa de StanchinaiD· 1 shared Harika GundlapalliiD· 1 shared Heeseon AniD· 1 shared Hilla SolomoniD· 1 shared Jacqueline A.M. SmithiD· 1 shared Julia Meredith· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alison M. SchramORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologybioRxivPreprintFeb 14, 2026

Coexistent PTEN and PIK3CA alterations hyperactivate mTORC1 signaling in endometrial cancers and cause their selective sensitivity to mTORC1 inhibition

Hilla Solomon, Radha Mukherjee, Yu Chi Yang…·Neal X. Rosen

This study shows that coexisting PTEN and PIK3CA mutations in endometrial cancers hyperactivate mTORC1, making them sensitive to mTORC1 inhibitors but not PI3K or AKT inhibitors.

DOI 10.64898/2026.02.12.705558

humanbulk RNA-seq

𝕏 PostBluesky